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Stem cells are self-renewing cells that can differentiate 
into specialized cell type(s). Pluripotent stem cells, i.e. 
embryonic stem cells (ESC) or induced pluripotent stem 
cells (iPSC) differentiate into cells of all three embryonic 
lineages. Multipotent stem cells, like hematopoietic stem 
cells (HSC), can develop into multiple specialized cells in 
a specific tissue. Unipotent cells differentiate only into 
one cell type, like e.g. satellite cells of skeletal muscle.
There are many examples of successful clinical applica-
tions of stem cells. Over million patients worldwide have 
benefited from bone marrow transplantations performed 
for treatment of leukemias, anemias or immunodeficien-
cies. Skin stem cells are used to heal severe burns, while 
limbal stem cells can regenerate the damaged cornea. 
Pluripotent stem cells, especially the patient–specific 
iPSC, have a tremendous therapeutic potential, but their 
clinical application will require overcoming numerous 
drawbacks. Therefore, the use of adult stem cells, which 
are multipotent or unipotent, can be at present a more 
achievable strategy. Noteworthy, some studies ascribed 
particular adult stem cells as pluripotent. However, de-
spite efforts, the postulated pluripotency of such events 
like “spore–like cells”, “very small embryonic-like stem 
cells” or “multipotent adult progenitor cells” have not 
been confirmed in stringent independent studies. Also 
plasticity of the bone marrow–derived cells which were 
suggested to differentiate e.g. into cardiomyocytes, has 
not been positively verified, and their therapeutic effect, 
if observed, results rather from the paracrine activity.
Here we discuss the examples of recent studies on adult 
stem cells in the light of current understanding of stem 
cell biology.
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DEFINITION OF STEM AND PROGENITOR CELL
Stem cell is an undifferentiated cell, which can self–
renew to replicate itself as well as give rise to the spe-
cialized cells under appropriate conditions (Weissman, 
2000). Progenitor cell lacks the self–renewal capability 
and often is unipotent — differentiates into only one 
cell type.
There are distinct kinds of stem cells according to 
their differentiation potential. Multipotent stem cells can 
differentiate into many cell types, but within a particular 
lineage. For example, the hematopoietic stem cells (HSC) 
can develop into red blood cells, white blood cells and 
platelets. Pluripotent stem cells are capable of giving rise 
to all cells of all tissue types (Jaenisch & Young, 2008). 
The examples of pluripotent stem cell are embryon-
ic stem cells (ESC) and induced pluripotent stem cells 
(iPSC) (Takahashi & Yamanaka, 2006).
Adult stem cells, which exist in the postnatal organ-
ism, are either multipotent or unipotent (Wagers & 
Weissman, 2004). The majority of known adult stem 
cells reside in the bone marrow. Among them are the 
multipotent HSC which have a capacity to regenerate 
the entire hematopoietic system (Bryder et al., 2006). Ac-
cordingly, therapeutic bone marrow transplantation has 
been used for more than 30 years, and more than mil-
lion patients suffering from different blood diseases have 
already been treated with transplantation of the BM or 
the mobilized BM-derived cells. The other adult stem 
cells that reside in the bone marrow are the mesenchy-
mal stem cells, defined also as the mesenchymal stromal 
cells (MSC), which can differentiate into the bone, chon-
drocytes and adipose cells (Bianco, 2014) (Fig. 1).
IN THE SEARCH FOR PLURIPOTENT ADULT STEM CELL
Multipotent or unipotent differentiation potential of 
adult bone marrow stem cells, like HSC or MSC, are 
very well known. Nevertheless, from time to time, it is 
claimed that the bone marrow cells can give rise to the 
cells of various organs and can differentiate not only 
into the blood or to the bone, but also to the blood ves-
sels (Asahara et al., 1999), muscles (Ferrari et al., 1998), 
cardiomyocytes (Orlic et al., 2001), skin (Kataoka et al., 
2003) or even can regenerate the kidney (Kale et al., 
2003), pancreas (Hess et al., 2003) and the nervous sys-
tem (Mezey et al., 2000). What are the scientific ration-
ales and proofs underlying such conclusions?
The vast differentiation potential of the bone marrow-
derived cells has often been suggested on the basis of 
experiments performed in cells cultured for the long 
time in vitro. Indeed, under such conditions, the expres-
sion of different markers can be demonstrated in the 
bone marrow cells. Recently our group has investigated 
the murine bone marrow-derived mesenchymal cells with 
CD45–CD34+CD14+ phenotype (Szade et al., 2011). To 
isolate this population we cultured plastic adherent bone 
marrow cells for at least 10 passages. During this long-
term culture the cells changed considerably their gene 
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expression profile (Szade et al., 2011). Such cultured 
population could differentiate into PPARγ+ adipocytes, 
what reflected the natural propensity of MSC. Under 
conditions promoting endothelial cell growth, we ob-
served upregulation of endothelial genes and some en-
dothelial function properties, like formation of tube-like 
structures on Matrigel, lectin binding or upregulation of 
VCAM-1 after TNFα stimulation. On the other hand, 
under neuronal differentiation conditions a few cells of 
this population expressed the neuronal markers (Szade et 
al., 2011).
Expression of different markers appearing in the 
in vitro cultures of bone marrow cells is considered as 
an indication of their vide differentiation potential and 
makes the rationale for application of such cells for the 
treatment of various conditions in organs in which the 
bone marrow cells do not reside naturally. Accordingly, 
the bone marrow cells have been used in experimental 
animals for treatment of myocardial infarction (Kamihata 
et al., 2001; Orlic et al., 2001), hind limb ischemia (Kalka 
et al., 2000), stroke (Chen et al., 2001), as well as liver 
(Petersen et al., 1999) or kidney injury (Kale et al., 2003). 
It has been claimed that the bone marrow cells have the 
capacity to differentiate into cardiomyocytes (Orlic et al., 
2001), endothelial cells (Asahara et al., 1997), neuronal 
cells (Mezey et al., 2000), hepatocytes (Petersen et al., 
1999) or kidney epithelial cells (Kale et al., 2003). Par-
ticularly the bone marrow MSC were regarded as cells of 
versatile properties (Jiang et al., 2002). Soon after the ex-
perimental studies, the clinical trials have been initiated.
Heme oxygenase-1 (HO-1), a stress-inducible enzyme 
degrading heme to carbon monoxide (CO), iron and bili-
verdin, has been previously demonstrated by us (Dulak 
et al., 2002; Józkowicz et al., 2003; Grochot-Przeczek et 
al., 2014) and others (Deramaudt et al., 1998; Bussola-
ti et al., 2004; Lakkisto et al., 2011) to play a protective 
role in cardiovascular system. The HO-1 activation can 
be cytoprotective, anti-apoptotic, anti-inflammatory and 
proangiogenic. HO-1 overexpression in the heart reduc-
es the cardiomyocyte death and fibrosis, improving the 
myocardial functions and preventing damages caused by 
the myocardial ischemia. The expression of HO-1 can be 
diminished under various pathological conditions; hence 
its upregulation is considered to be of therapeutic ben-
efit (reviewed in Dulak et al., 2008). Accordingly, several 
studies have previously demonstrated that application of 
bone marrow-derived mesenchymal cells overexpressing 
HO-1 improved the function of the ischemic murine 
heart (Tang et al., 2005). In line with those results we 
used porcine bone marrow cells for treatment of myo-
cardial infarction in pigs (Wojakowski et al., 2012). To 
improve the properties of the isolated cells we trans-
duced them with adenoviral vectors harboring HO-1. 
Control cells were transduced with vectors encoding 
green fluorescent protein (GFP). In vitro observations 
showed that the mesenchymal cells engineered to over-
express HO-1 formed better tube-like structures than 
their GFP expressing counterparts, what might indicate 
that HO-1 improves their angiogenic capacity (Woja-
kowski et al., 2012).
Such cells were used in pigs subjected to experimental 
myocardial infarction caused by occlusion of left anterior 
descending (LAD) artery by means of the balloon cath-
eter. The cells were injected through the catheter just be-
fore the blood flow was restored. Functional properties 
of the heart were assessed soon after treatment and two 
weeks later. One of the parameters used to assess the 
heart performance after myocardial infarction was left 
Figure 1. Major properties of stem cells.
Pluripotent stem cells under normal circumstances are not present in the adult organism — they are obtained as the result of isolation 
of the inner cell mass of the blastocyst (embryonic stem cells) or reprogramming of somatic cells by overexpression of defined transcrip-
tion factors (induced pluripotent stem cells). Adult stem cells are either multipotent or unipotent. In the same organ, e.g. in the skin, 
both multipotent and unipotent populations of stem cells can exist.
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ventricular ejection fraction (LVEF). Already 30 minutes 
after administration of cells we observed quite significant 
increase in LVEF (more than 10%), but only in those 
animals which received the mesenchymal cells overex-
pressing HO-1 (Wojakowski et al., 2012). The LVEF did 
not improve in animal hearts injected with control cells 
(Wojakowski et al., 2012).
Undoubtedly, despite the observed beneficial outcome, 
the effect observed already 30 minutes after cell delivery 
cannot be interpreted as a result of cell differentiation. 
Such an influence would require longer time to reveal. 
Interestingly, after two weeks, all animals which received 
either the control (GFP expressing) or HO-1 overex-
pressing cells, showed improved LVEF, however there 
were no differences between these groups. Nevertheless, 
this effect can be carefully interpreted as the influence 
of BM-derived mesenchymal cells on the heart function. 
Histological analysis of hearts evidenced that there were 
some GFP or HO-1 overexpressing cells in the infarct 
border zone, which phenotypically resembled endothelial 
cells or even cardiomyocytes (Wojakowski et al., 2012).
However, do our studies in murine (Szade et al., 2011) 
and porcine mesenchymal cells (Wojakowski et al., 2012), 
as well as numerous other similar observations (for re-
view see: Phinney & Prockop, 2007) indicate that that 
those cells are pluripotent and they can differentiate into 
many cell types, including endothelial cells, neuronal cells 
or cardiomyocytes?
Such conclusion cannot be drawn, because pluri-
potency has to be demonstrated at the single cell level 
(Fig. 2A). The pluripotent stem cells give rise to differ-
ent cell types under appropriate conditions. However, 
the populations of not sufficiently purified cells, like the 
bone marrow cells, may contain a mixture of unipotent 
or multipotent stem cells. When we differentiate such 
heterogeneous population, the various kinds of unipo-
tent stem cells can develop into different mature cells. 
In such case the appearance of different types of mature 
cells is not due to the differentiation of pluripotent stem 
cells, but due to differentiation of unipotent or multi-
potent stem cells and progenitors (Fig. 2B). Therefore, 
differentiation potential ascribed to the mixed population 
of cells (Fig. 2B) must not be confused with differentia-
tion potential of truly pluripotent stem cells (Fig. 2A). 
To demonstrate the latter, the clones derived from the 
single sorted cells of putative pluripotent stem cell popu-
lation have to be cultured under various conditions to 
demonstrate with sufficiently high statistical incidence 
the capability to form various types of mature cells 
(Fig. 2A).
Interpretation of our results should also take into con-
sideration that long-term in vitro culture could artificially 
affect the differentiation potential of MSC, and therefore 
any conclusions from in vitro experiments should not be 
directly extrapolated to in vivo function. Indeed, during 
the long-term culture the reprogramming events can ap-
pear (Li et al., 2007; Tolar et al., 2007; Dahl et al., 2008). 
Similarly, the expression of tissue-specific markers in cul-
tured cells can result from temporal activation of gene 
expression and does not point to the functional capacity 
Figure 2. Pluripotent stem cells vs. mixed population of multipotent/unipotent stem cells
(A) Pluripotency has to be always defined by the functional tests. One is the differentiation to various cell types of all three lineages (ec-
toderm, mesoderm and endoderm), which has to be shown on the single cell level. In this test the clones obtained from single sorted 
cells of purified population of the cells claimed to be pluripotent are cultured in various conditions allowing their differentiation into 
multiple cell types. Moreover, additional tests are required to fully confirm pluripotency, namely teratoma formation and blastocyst com-
plementation. Note, however, that chimera formation/complementation of tetraploid blastocyst are not applied to human pluripotent 
stem cells due to the ethical reasons.
(B) The mixture of the various populations of stem cells, e.g. bone marrow, cannot be interpreted as pluripotent. Such a mixture may 
contain the cells with limited (unipotent or multipotent potential) which when cultured and differentiated together can make the im-
pression of possessing the properties of pluripotent stem cells.
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of such cells. For example, MSC-derived cells express-
ing endothelial cell markers did not exert functional ac-
tivities of endothelial cells (Kachamakova-Trojanowska 
et al., manuscript in preparation). Furthermore, the ex-
pression of marker genes, used for labeling the injected 
cells and then detected in different cell types, as we saw 
in the porcine hearts, can be also explained by cell fu-
sion (Nygren et al., 2004). It has been convincingly dem-
onstrated that the administered cells can fuse with the 
mature cells in the tissues (Terada et al., 2002; Alvarez-
Dolado et al., 2003; Wang et al., 2003), what results in 
expression of tags of injected cells, but does not mean 
that the organ-specific mature cells had developed from 
the delivered stem cells. Again, in case of heterogene-
ous cell populations isolated from the bone marrow and 
injected into various organs, all conclusions concerning 
multipotent or pluripotent properties have to be driven 
with a great caution.
The claimed pluripotency of adult stem cells is par-
ticularly doubtful. In many reports pluripotency was pos-
tulated only on the basis of expression of some marker 
genes, like Oct-4 or Nanog, and the ability of population 
of cells, but not single cells, to differentiate into various 
cell types. The most stringent assays for pluripotency, 
namely the capacity to form teratomas after the injection 
into the immunodeficient mice (Müller et al., 2010) and 
the ability to complement blastocysts (Jaenisch & Young, 
2008) have rarely or never been applied to validate the 
different types of bone marrow-, cord blood-, or other 
organ-derived cells regarded by the authors as pluripo-
tent.
THE STORIES OF MAPC, SPORE-LIKE, AND VSEL CELLS
Despite the limitations and problems associated with 
ascribing the pluripotency to adult stem cells it is still 
believed that the dormant pluripotent stem cell popu-
lations, with very high therapeutic potential due to the 
broad differentiation plasticity, do exist in different adult 
organs.
In 2002 the group of Catherine Verfaillie described 
the cells they called multipotent adult progenitor cells 
(MAPC) (Jiang et al., 2002). Those cells, obtained after 
a very long-term in vitro culture, were able to differenti-
ate into all cell types and even to complement blastocyst 
(Jiang et al., 2002), what indicated they were really pluri-
potent. However, this study could not be reproduced by 
several independent groups (Check, 2007). There were 
also problems with the same images differentially de-
scribed in different publications (Baker, 2007).
Another group, led by Charles Vacanti, from Harvard 
University, has described so-called spore-like cells, which 
were very small and miraculously resistant to very harsh 
conditions, like very high or very low temperatures (Va-
canti et al., 2001). Despite the fact that this study has 
never been reproduced, Dr. Vacanti has claimed that 
spore-like cells are possibly represented by so-called 
STAP (stimulus-triggered acquisition of pluripotency) 
cells, described in 2014 as the pluripotent cells obtained 
by the short exposure of differentiated cells to the mild 
acidic conditions (Knoepfler, 2014). As known, the story 
of STAP cells has ended in very fast retraction of the 
papers (Obokata et al., 2014a, 2014b), what will be dis-
cussed later in this text.
An example of cells whose pluripotency could not 
be validated by independent groups are so called very 
small embryonic-like cells (VSELs) described in 2006 by 
Mariusz Ratajczak and co-workers (Kucia et al., 2006). 
Originally, VSELs were recognized as pluripotent on ba-
sis of expression of Oct-4 and other embryonic markers 
(SSEA-1, Nanog, Rex-1), and were shown to differenti-
ate into cells of all three lineages in vitro (cardiomyocytes, 
pancreatic and neural cells) (Kucia et al., 2006). They are 
described as very small events (of diameter of 3.6 µm 
in mice, although the indicated sizes vary), much smaller 
than hematopoietic stem cells (Zuba-Surma et al., 2009). 
Further studies performed by the same group showed 
that VSELs can be differentiated into cells expressing 
markers of different lineages (Dawn et al., 2008; Huang et 
al., 2010; Ratajczak et al., 2011a), and their differentiation 
into hematopoietic stem cells was described (Ratajczak 
et al., 2011b). Although the freshly isolated VSELs were 
not able to reconstitute blood of lethally irradiated mice, 
the authors suggested that the hematopoietic pre-differ-
entiation of VSEL population on OP9 cells can induce 
their hematopoietic potential (Ratajczak et al., 2011b).
We analyzed the VSELs from murine bone marrow 
using the initially proposed markers (Kucia et al., 2006): 
expression of Sca-1, lack of CD45 and lineage antigens 
(Szade et al., 2013). Such defined population of small 
cells was still heterogeneous with cell subset expressing 
also c-Kit, antigen characteristic for hematopoietic line-
age. We have characterized these cells, using the strin-
gent approach to investigate the differentiation potential 
— the single cell assays. We sorted single Lin-CD45-
Sca-1+c-Kit+ small cells or HSC from murine bone 
marrow and cultured them under appropriate conditions 
to determine whether they can differentiate into blood 
cells. Out of 76 single Lin-CD45-Sca1+c-Kit+ cells we 
have not seen any colony, whereas 50% of single HSC 
formed colonies of hematopoietic cells. Additionally, we 
performed pre-differentiation of whole VSEL population 
(Lin-CD45-Sca1+ small cells) on OP9 and then checked 
their hematopoietic potential, sorting up to 100 cells 
per well. Again, we observed no colonies, in contrast to 
HSC. Hence, we did not confirm that murine bone mar-
row derived VSELs are stem cells with hematopoietic 
potential (Szade et al., 2013).
Pluripotency of VSELs was postulated owing to 
expression of Oct-4 (Kucia et al., 2006). Indeed, this 
gene is expressed in pluripotent stem cells, namely 
iPS and embryonic stem cells, where its expression is 
high and demonstrated by whole population. There 
are several critical issues that have to be considered 
when analyzing the Oct-4 expression (Liedtke et al., 
2008). First, the level of Oct-4 has to be sufficiently 
high to maintain pluripotency. Second, different vari-
ants of Oct-4 exist, which not necessarily are connect-
ed to pluripotency (Liedtke et al., 2008). Therefore, it 
is important to use the correct tools to demonstrate 
the expression of a proper Oct-4 form, namely Oct-
4A, which is an isoform associated with pluripotency 
of cells (Liedtke et al., 2007, 2008). Fortunately, vari-
ous Oct-4 isoforms are relatively easily distinguishable 
by PCR when using well-designed primers. Oct-4A 
has E1 exon, which does not exist in another form – 
Oct-4B. Therefore, one can design the primers, which 
discriminate Oct-4A from Oct-4B. However, in the 
original paper describing VSELs the primers recog-
nized sequences localized in exons 4 and 5, which are 
present in both variants of Oct-4 (Kucia et al., 2006). 
Keeping in mind that it is very difficult or even im-
possible to distinguish Oct-4A and Oct-4B proteins 
with antibodies currently available (Liedtke et al., 
2007, 2008), no data have convincingly demonstrated 
that Lin-CD45-Sca1+ cells express Oct-4A.
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We performed analysis of Oct-4A expression in 
whole bone marrow, sorted VSEL population, as well 
as in single Lin-CD45-Sca1+ small cells. Embryonic 
stem cells (ESD3) were included as a positive con-
trol (Szade et al., 2013). When we used primers ap-
plied in the original study describing VSELs (Kucia et 
al., 2006), we detected the expected PCR product in 
embryonic stem cells, whole bone marrow and sorted 
VSEL population; however, this product was tran-
scribed from a pseudogene template and appeared also 
if no reverse transcription was performed. Therefore, 
these primers cannot be used to determine the expres-
sion of Oct-4. Importantly, when we used other prim-
ers, specific to Oct-4A isoform, we detected Oct-4A 
only in ESD3 embryonic stem cells, but not in whole 
bone marrow, sorted VSEL population or single Lin-
CD45-Sca1+ cells (Szade et al., 2013).
So what are VSELs? We demonstrated that the 
population gated as VSELs was enriched in the ap-
optotic, Annexin V positive cells. Moreover, even 
Annexin-V negative cells showed a high level of chro-
matin fragmentation (Szade et al., 2013). Interestingly, 
two months after our study the independent analysis 
by Irving Weissman’s group from Stanford Univer-
sity, demonstrated that the events gated as VSELs 
are mainly the debris and fragmented cells with re-
duced DNA content (Miyanishi et al., 2013). In this 
study Miyanishi and co-workers additionally showed 
that VSELs did not display functional activity, did not 
form spheres or express Oct-4 and could not differ-
entiate into blood cells upon transplantation into ir-
radiated mice. The authors critically addressed techni-
cal issues connected with measuring size of cells by 
flow cytometry and used additional transgenic mouse 
models, like Oct4-EGFP and H2K-BCL-2 to verify the 
VSEL hypothesis. Furthermore, they even searched 
for pluripotent cells with less stringent gating on cell 
size and CD45 expression. However, all these at-
tempts failed to confirm the existence of pluripotent 
VSELs what was in full agreement with our conclu-
sions (Miyanishi et al., 2013).
Those studies (Szade et al., 2013; Miyanishi et al., 
2013) are in line with results that undermined the 
properties of human umbilical cord blood-derived 
VSELs. The group of Rudiger Alt from Leipzig Uni-
versity demonstrated that the cord blood-derived 
Lin-CD45- VSELs lack the expression of CD34 and 
CD133 markers in contrast to original reports on hu-
man VSELs (Danova-Alt et al., 2012). Additionally, 
this study showed that VSELs do not express Oct-4, 
neither proliferate nor differentiate in vitro in variety 
of culture media, and have no markers of embryonic, 
neuronal, mesenchymal and hematopoietic stem cells 
(Danova-Alt et al., 2012). They also demonstrated that 
VSEL transcriptome is very much different from that 
of embryonic and adult stem cells and even of mature 
tissues, according to clustering analysis. The authors 
concluded that VSELs are dysfunctional, as this popu-
lation is enriched in aneuploid cells (Danova-Alt et al., 
2012).
Finally, the group of Alejandro Madrigal from Antony 
Nolan Research Institute in London has also shown that 
human umbilical cord blood population with Lin-CD45- 
phenotype ascribed to VSELs is heterogeneous and neg-
ative for CD133. This group also was not able to culture 
Lin-CD45- cells under any of tested conditions and con-
cluded that these cells lacked self-renewal capacity (Alva-
rez-Gonzalez et al., 2013). Thus, all these data indicate 
that also human VSELs are not the stem cells.
METHODOLOGICAL STRINGENCY IN STEM CELL FIELD
Could it be any scientific explanation for the results 
demonstrating pluripotent properties of VSELs? The 
studies about rare stem cell populations often involve 
cell sorting and it is important to understand the limi-
tations of this technique, before generalized conclu-
sions are stated. Long sorts, required to isolate number 
of rare populations, like VSELs, are never 100% pure. 
Therefore, among sorted VSELs there could be few real 
HSC cells that can differentiate into the blood cells. This 
could be misleadingly interpreted as blood differentiation 
potential of VSEL population. The parallel to tomato 
juice, to which we put a drop of tabasco, can be illus-
trative. The juice is hot, not because of the tomato, but 
because of the drop of tabasco. So if in the tomato juice 
of so called VSELs there are few “tabasco drops” of real 
hematopoietic stem cells, they may give rise to different 
blood cells under appropriate conditions.
There are other, more probable than pluripotency, ex-
planations of studies indicating broad plasticity of adult 
stem cells. Often, the conclusions are based solely on 
expression of markers, what cannot be considered clear-
ly as a definite proof for pluripotency. In various cells 
types some of such marker genes are indeed expressed, 
but at the very low level, what also does not have any 
functional meaning (Kaltz et al., 2008). The expression 
of some genes can be the result of environmental in vitro 
conditions, which induce transcription of those genes, 
but do not induce pluripotency of those cells. Moreo-
ver, the used antibodies and primers might be not spe-
cific enough (Liedtke et al., 2008). Finally, the proof of 
the pluripotent or multipotent characteristic of the cells 
requires additional stringent tests like functional assays 
(chimera formation or blastocyst complementation and 
teratoma formation for pluripotent cells) (Jaenisch & 
Young, 2008) together with the single cells assays of dif-
ferentiation.
“REPAIRING” HEART BY BONE MARROW
Another story largely advertised in the field of regen-
erative medicine concerns the application of bone mar-
row cells for the treatment of myocardial infarction. In 
2001 Pierro Anversa’s group, then at Valhalla Medi-
cal College, published a paper demonstrating that bone 
marrow cells injected into the heart could differentiate 
into cardiomyocytes and improve cardiac function (Orlic 
et al., 2001). Soon after that the clinicians have started 
the clinical trials, in which the patients after myocar-
dial infarction were treated with the injection of their 
own bone marrow cells (Strauer et al., 2002; Assmus 
et al., 2002; Perin et al., 2003; Stamm et al., 2003; Wol-
lert et al., 2004). The clinical trials were initiated despite 
the fact that this experimental study has not been really 
confirmed by independent laboratories. The verification 
came three years later: Charles Murry group from Seattle 
(Murry et al., 2004), and two other groups, Balsam and 
Robins including Irving Weissman contribution (Balsam 
et al., 2004) and Nygren and co-workers (Nygren et al., 
2004), also from the United States, showed that HSCs 
do not transdifferentiate into cardiomyocytes. Murry 
group used bone marrow from LacZ-expressing mice 
(Murry et al., 2004), the group of Balsam and Robins 
used GFP-expressing mice (Balsam et al., 2004). When 
they injected HSC into mice that underwent myocardial 
infarction, they did not observe any differentiation into 
cardiac myocytes. Injected cells simply differentiated into 
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the blood cells (Balsam et al., 2004), or fused with the 
cardiac cells (Nygren et al., 2004). Any beneficial effect 
could not be thus ascribed to the differentiation poten-
tial of bone marrow cells.
Nevertheless, clinical trials have started despite the 
above concerns, mostly in Europe (Strauer et al., 2002; 
Assmus et al., 2002; Stamm et al., 2003; Wollert et al., 
2004). The studies have been continued and not halted 
despite inconsistent results. Usually, the improvement of 
the LFEV was shown as a marker of the effectiveness 
of the BM-cell treatment. However, in some studies the 
LVEF was increased after BM cell injection by 5–10%, 
while in other studies LVEF did not increase at all (Jong 
et al., 2014). The effects observed were usually transient. 
Reproducibly, the studies were in general safe and did 
not cause any harm to the patients. However, the valid-
ity of the trials performed by Strauer et al. (Strauer et al., 
2002) has been questioned (Grens, 2015).
Recently, the group of Darrel Francis from Imperial 
College in London analyzed the performed clinical tri-
als, in which BM cells were used for treatment of myo-
cardial infarction (Nowbar et al., 2014). This analysis has 
revealed the interesting but alarming correlations. It has 
been shown that the more discrepancies of various types 
were found in the trial, the more effective therapy was 
claimed. In trials, in which Francis and coworkers did 
not find any mistakes, no improvements in LVEF were 
reported. However, the other trials where mistakes and 
inconsistencies were found, like untrue patient descrip-
tions (e.g. dead patients reported as alive patients; lack 
of proper description of the number of patients with the 
given sex, etc.) demonstrated significant improvement in 
LVEF. Hence, the more errors were found in the trial, 
the better LVEF “improvement” was observed (Nowbar 
et al., 2014). In 133 reports from 49 trials more than 600 
discrepancies were found, and, what is alarming, only 
five trials were found without errors. They showed no 
change in LEEV (Nowbar et al., 2014).
Various examples described above indicate that we 
are faced with a sort of never-ending story in the field 
of stem cell applications for regenerative medicine. Ini-
tially, animal studies provide feasibility for this approach. 
Such studies, performed usually in mice, show often a 
dramatic improvement in infarcted heart function after 
BM cell application. However later, the results are often 
not reproduced in studies in large animals, where only 
moderate improvement is observed. In clinical trials, in 
phase 1 there is a decent improvement, but phases 2 and 
3 do not confirm any beneficial effects.
Despite these negative results and studies undermin-
ing the effectiveness of such therapies, once initiated, 
the clinical trials tend to thrive. Currently, the European 
Union has funded a new big clinical study called BAMI 
(clinicaltrial.gov, number: NCT01569178), that involves 
3 000 persons and costs 6 mln euro (Choudry & Mathur, 
2011). The aims stated are, once again, defined for re-
solving whether a mix of autologous bone marrow cells 
can help after myocardial infarction. In the opinion of 
some clinicians, this study is unethical, because it has 
been already shown that such approach did not work 
(Couzin-Frankel, 2014).
Importantly, negative data are often not acknowl-
edged in the field of stem cells research. The researchers, 
whose works do not confirm the original “attractive” hy-
pothesis are claimed to be wrong only because they did 
not confirm the properties on the “miracle stem cells” 
claimed to be the “Holy Grails”, like was often stated 
for VSELs. People who present negative data are often 
attacked (see comments in: Abbott, 2013). Accordingly, 
Charles Murry, whose work demonstrated that Dr. An-
versa data are misleading, said: “I was struck by how little 
effect the negative results had on a field that was gathering mo-
mentum”.
HYPES IN PURSUIT FOR PLURIPOTENCY
There is the most recent story, which illustrates 
very well what can happen when there are enormous 
hopes and expectations in the stem cell field. At the 
end of January 2014 two papers were published in 
Nature (Obokata et al., 2014c, 2014d) in which Japa-
nese-American group reported that adult somatic cells, 
just by the brief exposure to the acidic conditions (pH 
4.5) for 20 minutes, could be reprogrammed into the 
so-called STAP cells (STAP states for stimulus-trig-
gered acquisition of pluripotency). They were claimed 
to contribute to embryo development similarly to the 
induced pluripotent stem cells (iPSCs) (Obokata et al., 
2014c).
Moreover, investigators proposing the STAP hy-
pothesis suggested that these cells could be reversed 
even to the totipotent state, as they were able in their 
hands to contribute both to embryo and placenta. 
The first author of those papers was Haruko Obokata 
from RIKEN institute in Kobe, and Yoshiki Sasai and 
Teruhiko Wakayama were among the senior authors. 
Charles Vacanti, mentioned already above, was an au-
thor in both studies, being a senior author in one of 
the papers.
As expected, such promising studies acquired a lot 
of attention and immediately many scientists wanted to 
reproduce them. Quickly it became clear that no one 
was able to confirm the study. A few weeks after the 
publication, Teruhiko Wakayama raised the alarm that 
he was not able to reproduce the experiment when he 
was working with the cells prepared by him, not with 
the cells that he got from Dr. Obokata. RIKEN institute 
immediately initiated the procedure very adequate to the 
situation: they started to investigate if the experiments 
were performed in accordance with scientific stringency. 
Already in the beginning of April 2014 RIKEN commis-
sion concluded that there were important inconsistencies 
and errors in these studies (Cyranoski, 2014a).
Haruko Obokata was accused of being responsible 
for unaccepted approach to research, but also the sen-
ior investigators were considered of not properly super-
vising the project. The publications have been finally 
withdrawn on the July 2nd 2014 (Cyranoski, 2014b). 
Nevertheless, Charles Vaccanti, who described so-called 
spore-like cells, was very much opposing that action 
(Normile & Vogel, 2014). Dr. Vaccanti still claimed 
that STAP cells can be generated and he believes those 
cells exist in the body in the form of very small spore-
like cells. The story has a very dramatic end. In August 
2014, Yoshiki Sasai, a co-author of those withdrawn pa-
pers, a very talented developmental biologist with great 
scientific achievements committed suicide, leaving a let-
ter to Haruko Obokata, asking her to repeat the results 
(Cyranoski, 2014c). In December 2014 RIKEN finally 
announced that the STAP cells cannot be reproduced, 
and it has been revealed that the cells used by Oboka-
ta were in fact the murine embryonic stem cells (Cyra-
noski, 2014d). Obokata was dismissed from her work in 
RIKEN. Dr. Vacanti, who is highly responsible for the 
reported problems, took a sabbatical from Harvard. It is 
not known if Harvard authorities are doing any investi-
gations.
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FUTURE OF STEM CELL THERAPY
Despite these negative examples of research in stem 
cells, it should be underlined that stem cell therapies 
have already been proven to be successful. There are ef-
fective therapies based on the stem cells, such as hemat-
opoietic bone marrow transplantation, skin regeneration 
from cultured progenitors or application of limbal stem 
cells for treatment of damaged cornea (Rama et al., 2010; 
Bianco et al., 2014). On the other hand, there are many 
other approaches, mostly not mentioned here, that had 
never been proved and with no evidence that they repre-
sented the action of the stem cells.
We have the real pluripotent stem cells, like human 
embryonic stem cells, which under appropriate condi-
tions can differentiate into all cell types, and which can 
be potentially used for therapeutic purposes. Some clini-
cal trials using ESC have been started (Schwartz et al., 
2012). It is a justified hope that they can lead to the 
treatment. Finally, we can generate the iPSCs, obtained 
for the first time by Yamanaka and Takahashi (Takahashi 
& Yamanaka, 2006), whose large potential was already 
demonstrated and validated by numerous independent 
investigators. iPSCs can be used not only for therapy but 
also for disease modeling and drug research.
Do we need the “Holy Grail” in the stem cell research 
and regenerative medicine? In fact, there is no convinc-
ing evidence for “Holy Grail” among adult stem cells. 
Adult stem cells like HSC and MSC, or satellite cells in 
the muscle and other tissue-specific stem cells have lim-
ited differentiation potential and they are not pluripotent. 
However, the multipotency or even unipotency of adult 
stem cells do not preclude their therapeutic application 
and are rather a favorable feature. The only limitation is 
that they should be applied in a tissue specific manner. 
However, we do not need to use the bone marrow for 
treatment of the cornea. We have corneal stem cells that 
can be applied for the treatment of the damaged eye.
It is a high responsibility of scientists and physicians 
not to make unjustified hope and not to generate hype 
on the properties and possible applications of any stem 
cells. 
Therefore, for the sake of scientific purity and benefit 
of the patients we have to go back to the methodologi-
cal rules established long time ago, but still valid. The 
so-called Ockham’s razor principle has to be used in 
the field of stem cell research: “Pluralitas non est ponenda 
sine neccesitate” (attributed to William of Ockham, c. 1287 
–1347; Spade & Panacio, 2011) (“Entities should not be 
multiplied unnecessarily”). As the field of stem cells is filled 
with enormous expectations and, unfortunately, also nu-
merous hypes, such a methodological stringency is of the 
highest importance.
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